Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMERS-1: Timing of Anticoagulation After EVT for Acute Ischemic Stroke With Atrial Fibrillation
NCT07139301Active, not recruiting
- Sponsor
- Capital Medical University
- Start
- Sep 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of Draxaban in ischemic stroke (2 arms), sponsored by Capital Medical University. Primary endpoint: Composite outcome of recurrent ischemic stroke, symptomatic intracranial hemorrhage, and all-cause death at 90 days. Started Sep 2025; status: active, not recruiting.
02
Drugs
Draxaban
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07139301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07139301.